Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave

11. November 2026 aktualisiert von: University of Aarhus

Effectiveness of Focused Acceptance and Commitment Therapy With Workplace Involvement for Employees on Sick Leave Due to Common Mental Disorders: A Randomized Controlled Trial

The investigators aim to evaluate the effectiveness of Focused Acceptance and Commitment Therapy combined with workplace involvement (FACT-WI) in reducing perceived stress, improving psychological well-being, and supporting return to work among employees on sick leave due to common mental disorders.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

In the present study, participants will be randomly assigned to one of two groups, receiving either Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) or treatment as usual (TAU). FACT-WI will be delivered flexibly according to individual needs over a three-month period, with the possibility of involving the participant's immediate manager to support return to work.

  1. It is hypothesized that FACT-WI will be more effective than TAU in reducing perceived stress and improving quality of life over time.
  2. It is hypothesized that participants receiving FACT-WI will return to work more quickly than participants receiving TAU, including both part-time and full-time return to work.
  3. The feasibility and acceptability of FACT-WI will be evaluated.
  4. The number and duration of sessions received, as well as the extent and format of workplace involvement, will be explored.
  5. Managers' experiences of workplace involvement, including its perceived relevance, usefulness, barriers, facilitating factors, and suggestions for improvement, will be explored.

Studientyp

Interventionell

Einschreibung (Geschätzt)

70

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

  • Name: Astrid Olesen Liboriussen, MSc
  • Telefonnummer: 004553356030
  • E-Mail: astridol@psy.au.dk

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

Inclusion criteria are (i) age ≥ 18 years, (ii) currently being on part-time or full-time sick leave at the start of the study, (iii) symptoms of anxiety measured with the Generalized Anxiety Disorders (GAD ≥ 9) questionnaire and/or symptoms of depression assessed with the Patient Health Questionnaire (PHQ-9 ≥ 10) and/or symptoms of stress measured with the Perceived Stress Scale (PSS-10 ≥ 17), (iv) Danish language proficiency, (v) ability and willingness to give informed consent, (vi) access to either a smartphone, tablet, or computer with video camera. (vii) Be currently employed and anticipate to continue employment within the organizational setting. (viii)) have been employed in the current organization for a minimum of six months.

Exclusion Criteria:

Exclusion criteria are: (i) currently receiving other psychotherapy for the same problem, (iii) a history of bipolar disorder, (ii) current or past psychotic disorder, (iv) substance abuse or dependence judged to require treatment, (v) suicide risk requiring immediate hospitalization. (vi) being on sick leave for more than 4 months at the time of inclusion. (vii) a somatic or medical condition that is considered to prevent the participant from RTW. (viii) PTSD symptoms that re-quire treatment beyond the scope of the brief intervention. (ix) having an active Section 56 agreement under the Danish Sickness Benefits Act at the time of inclusion. In addition, potential participants must be clinically assessed as suitable for this brief intervention.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: FACT-WI

Brief ACT-based intervention with optional workplace involvement

Focused Acceptance and Commitment Therapy with Workplace Involvement (FACT-WI) is a brief, flexible intervention based on Acceptance and Commitment Therapy (ACT). The intervention aims to increase psychological flexibility, reduce psychological distress, and support return to work.

Participants receive up to 300 minutes of online therapist contact over a period of three months. The intervention is tailored to individual needs and focuses on identifying psychological and work-related barriers, promoting values-based action, and developing strategies to support return to work.

Workplace involvement is offered when relevant and may include written communication with the participant's immediate manager, verbal contact, or a joint meeting between the participant, manager, and therapist. The purpose is to address work-related barriers and facilitate a sustainable return to work. Workplace involvement is voluntary and requires the participant's consent.

Sonstiges: Treatment as Usal (TAU)

Treatment as usual (TAU), including any support or services ordinarily available to employees on sick leave.

Participants allocated to the control group will receive treatment as usual (TAU). They will have access to the usual healthcare and support services available to employees on sick leave, including relevant services provided by the municipality, workplace, or healthcare system.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Perceived stress
Zeitfenster: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Perceived Stress Scale-10 (PSS-10; Cohen & Williamson, 1988). The scale consists of 10 items rated from 0 to 4, resulting in a total score ranging from 0 to 40. Higher scores indicate higher levels of perceived stress (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
Quality of life (well-being)
Zeitfenster: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

the World Health Organization-5 questionnaire (Bech, 1999; Topp et al., 2015; WHO-5). 5 items are rated on a scale from 0 to 5 with total scores ranging from 0 to 25. Higher scores are indicative of higher levels of life quality (i.e., a positive outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to Return to Work (RTW)
Zeitfenster: From baseline to 3 months (post-treatment) and 6 months (follow-up).

Time to return to work, including both part-time and full-time return to work. Using administrative sickness absence records.

From baseline to 3 months (post-treatment) and 6 months (follow-up).
Sickness Absence Percentage
Zeitfenster: At 3 months (post-treatment) and 6 months (follow-up).

Percentage of scheduled working time lost due to sickness absence, based on administrative sickness absence records. Higher percentages indicate greater sickness absence (i.e., a negative outcome).

At 3 months (post-treatment) and 6 months (follow-up).
Depressive symptoms
Zeitfenster: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

Patient Health Questionnaire-9 (Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000; PHQ-9). 9 items are rated on a scale from 0 to 3, with a potential total range from 0 to 27. Larger scores mean more depressive symptoms (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Anxiety symptoms
Zeitfenster: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

General Anxiety Disorder-7 (Spitzer et al., 2006; GAD-7). 7 items are rated on scale from 0 to 7 with total scores ranging from 0 to 21. Higher scores are indicative of more symptoms of GAD (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Valued Living
Zeitfenster: Change from baseline to 3 months (post-treatment) and 6 months (follow-up)

Valuing Questionnaire (Smout et al., 2014; VQ). 10 items are rated on a scale from 0 to 6 with total scores ranging from 0 to 60. Higher scores a indicative of actions/life being guided by personally held values (i.e., a positive outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up)
Harm/negative effects
Zeitfenster: Measured once at post-treatment (3 months), in the intervention group only.

The Negative Effects Questionnaire (Rozental et al., 2019; NEQ). 32 questions are answered yes/no. If yes, items are rated on a scale from 1 to 5 and participants are asked if the negative effect experience can be attrubuted to the treatment or other crcumstances. Total scores range from 32 to 160 with higher scores indicating more negative effects (i.e., a negative outcome).

Measured once at post-treatment (3 months), in the intervention group only.
Experiental Avoidance
Zeitfenster: Change from baseline to 3 months (post-treatment) and 6 months (follow-up).

Brief Experiential Avoidance Questionnaire (BEAQ; Gámez et al., 2014). The questionnaire consists of 15 items rated from 1 to 6, resulting in a total score ranging from 15 to 90. Higher scores indicate greater experiential avoidance (i.e., a negative outcome).

Change from baseline to 3 months (post-treatment) and 6 months (follow-up).
Client Satisfaction Questionnaire
Zeitfenster: Measured once at 3 months (follow-up), in the intervention group only.

Client Satisfaction Questionnaire-8 (CSQ-8; Larsen et al., 1979). The questionnaire consists of eight items rated from 1 to 4, resulting in a total score ranging from 8 to 32. Higher scores indicate greater satisfaction with the intervention. The questionnaire will be administered to participants in the FACT-WI group only.

Measured once at 3 months (follow-up), in the intervention group only.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

25. Januar 2027

Primärer Abschluss (Geschätzt)

1. August 2028

Studienabschluss (Geschätzt)

1. August 2028

Studienanmeldedaten

Zuerst eingereicht

11. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. November 2026

Zuerst gepostet (Tatsächlich)

19. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • FACT-WI

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .